周燕;刘宇;魏玲玲;李仕强;

• 1:陆军军医大学第二附属医院肝胆外科
• 2:陆军军医大学第二附属医院神经内科
• 3:重庆九龙坡区第二人民医院消化疾病中心

摘要(Abstract)：

目的分析扩大淋巴结清扫对腹腔镜下肝门胆管癌(hilar cholangiocarcinoma,HCC)根治术患者临床预后的随访结果。方法回顾性分析2015年3月至2018年3月陆军军医大学第二附属医院收治的104例HCC患者的临床资料,按照患者术中淋巴结清扫范围,将接受扩大淋巴结清扫的患者纳入扩大组(61例),将接受区域淋巴结清扫的患者纳入区域组(43例)。对比两组患者手术情况、术后恢复情况、术后并发症发生情况以及术后3年生存情况。结果扩大组患者淋巴结清扫数量、阳性淋巴结清扫数量均显著多于区域组(均P<0.05)。两组患者重症监护病房住院天数、总住院天数、术后并发症发生率、术后3年生存率比较差异均无统计学意义(均P>0.05)。扩大组术后3年内死亡患者中,11例(34.38%)为肝内复发;区域组术后3年内死亡患者中,9例(37.50%)为肝内复发。结论扩大淋巴结清扫能够增加腹腔镜下HCC根治术中淋巴结清扫数量和阳性淋巴结清扫数量,其术后恢复情况和并发症发生风险与区域淋巴结清扫相当,但这一术式并未对患者3年生存率带来积极影响。

关键词(KeyWords)： 扩大淋巴结清扫;腹腔镜;肝门胆管癌根治术;随访

Abstract:

Keywords:

基金项目(Foundation):

作者(Authors): 周燕;刘宇;魏玲玲;李仕强;

参考文献(References)：

• [1]BIRD N T E,MCKENNA A,DODD J,et al.Meta-analysis of prognostic factors for overall survival in patients with resected hilar cholangiocarcinoma[J].J Br Surg,2018,105(11):1408-1416.
• [2]SUN Z,FENG Y,LIU H,et al.Analysis of treatment methods and prognostic factors in 354 cases of hilar cholangiocarcinoma:A cohort study[J].J Cancer Res Ther,2020,16(2):230-237.
• [3]李相成，王艺睿.肝门部胆管癌淋巴结清扫的共识和争议[J].中国普外基础与临床杂志，2020，27(3)：265-270.
• [4]ZABOROWSKI A,HENEGHAN H M,FIORE B,et al.Neoadjuvant Chemoradiotherapy and Liver Transplantation for Unresectable Hilar Cholangiocarcinoma:the Irish Experience of the Mayo Protocol[J].Transplantation,2020,104(10):2097-2104.
• [5]TRAN T B,ETHUN C G,PAWLIK T M,et al.Actual 5-Year Survivors after Surgical Resection of Hilar Cholangiocarcinoma[J].Ann Surg Oncol,2019,26(2):611-618.
• [6]LI J,ZHOU M H,MA W J,et al.Extended lymphadenectomy in hilar cholangiocarcinoma:What it will bring?[J].World J Gastroenterol,2020,26(24):3318-3325.
• [7]ZHANG C W,LIU J,HONG D F,et al.Pure laparoscopic radical resection for type Ⅲa hilar cholangiocarcinoma[J].Surg Endosc,2018,32(3):1581-1582.
• [8]ZHOU R,LU D,LI W,et al.Is lymph node dissection necessary for resectable intrahepatic cholangiocarcinoma?A systematic review and meta-analysis[J].HPB (Oxford),2019,21(7):784-792.
• [9]孟令军，张晓荣，杨保金.扩大的腹主动脉旁淋巴结清扫可改善Bismuth Ⅰ/Ⅱ型肝门部胆管癌患者术后生存[J].实用肝脏病杂志，2018，21(5)：761-764.
• [10]李富宇，程南生，马文杰.肝门部胆管癌根治与淋巴结清扫范围[J].中国普外基础与临床杂志，2018，25(8)：993-996.
• [11]杨娟，母齐鸣，谭琴.影响肝内胆管癌手术预后的危险因素Logistic回归分析[J].江苏大学学报(医学版)，2019，29(2)：161-165.
• [12]ZHANG X F,BEAL E W,CHAKEDIS J,et al.Defining Early Recurrence of Hilar Cholangiocarcinoma After Curative-Intent Surgery:a Multi-institutional Study from the US Extrahepatic Biliary Malignancy Consortium[J].World J Surg,2018,42(9):2919-2929.
• [13]张珅瑜，王继洲，陆朝阳，等.肝门部胆管癌淋巴结清扫的研究进展[J].中华肝胆外科杂志，2020，26(12)：957-960.
• [14]汤朝晖，魏妙艳，唐陈伟，等.肝门部胆管癌根治术区域淋巴结清扫范围探讨[J].中国普外基础与临床杂志，2018，25(7)：775-778.
• [15]FENG J W,YANG X H,WU B Q,et al.Progress in diagnosis and surgical treatment of perihilar cholangiocarcinoma[J].Gastroenterol Hepatol,2019,42(4):271-279.
• [16]WANG W,FEI Y,LIU J,et al.Laparoscopic surgery and robotic surgery for hilar cholangiocarcinoma:an updated systematic review[J].ANZ J Surg,2021,91(1-2):42-48.
• [17]HA S,HONG M E,PARK J K.Angioimmunoblastic T Cell Lymphoma Mimicking Postoperative Lymph Node Recurrence in Cholangiocarcinoma[J].Korean Society of Gastrointestinal Cancer,2021,9(1):33-36.
• [18]WANG K,ZHANG H,XIA Y,et al.Surgical options for intrahepatic cholangiocarcinoma[J].Hepatobiliary Surg Nutr,2017,6(2):79-90.